目的 研究甲磺酸阿帕替尼片联合紫杉醇注射液对非小细胞肺癌患者的疗效及血清因子的影响。方法 选择2013年3月-2018年3月在榆林市第一医院肿瘤诊疗中心治疗的80例非小细胞肺癌患者为研究对象，按照随即数字法分为对照组和观察组，每组各40例。对照组患者给予紫杉醇注射液单药化疗，按175 mg/m²将紫杉醇溶于生理盐水中稀释，静脉滴注3 h，每周1次。观察组在对照组的基础上口服甲磺酸阿帕替尼片，850 mg/次，1次/d。3周为1个疗程，两组均治疗3个疗程。观察两组化疗后的临床疗效，比较两组化疗前后的血清因子水平，包括血管内皮生长因子（VEGF）、基质金属蛋白（MMP-9）、细胞角蛋白19片段（CYFRA21-1）和血清癌胚抗原（CEA）和化疗期间不良反应发生情况。结果 化疗后，观察组患者的总有效率为82.5%，显著高于对照组的62.50%，两组比较差异具有统计学意义（P<0.05）。化疗后，两组患者VEGF、MMP-9、CYFRA21-1和CEA水平较治疗前均显著降低（P<0.05），且观察组血清学指标水平显著低于对照组（P<0.05）。两组在化疗期间均出现白细胞减少、血小板减少、关节痛等不良反应，且无显著差异，给予对症治疗后均缓解。结论 甲磺酸阿帕替尼片联合紫杉醇注射液化疗对非小细胞肺癌疗效较好，能有效改善患者血清学指标，值得在临床应用和推广。

Objective To investigate effect on clinical effect and serum factor in treatment of NSCLC patients by using Paclitaxel Injection combined with Apatinib Mesylate Tablets. Methods Selected 80 cases of patients with NSCLC who were treated in the cancer center of The First Hospital of Yulin from March 2013 to March 2018, divided into control (40 cases) and observation (40 cases) groups randomly. The control group was given Paclitaxel Injection single drug chemotherapy. 175 mg/m² paclitaxel was dissolved in normal saline, and intravenously dripped for 3 h, once a week. The observation group were po administered with Apatinib Mesylate Tablets on the basis of control group, 850 mg/time, once daily. 3 weeks is a course of treatment, both groups were treated for 3 courses. After chemotherapy, the clinical effect was evaluated, and serum factor levels (VEGF, MMP-9, CYFRA21-1 and CEA) and adverse reactions in two groups before and after chemotherapy were compared. Results After chemotherapy, the total effective rate of the observation group was 82.50%, significantly higher than 62.50% in the control group, and there was difference between two groups (P<0.05). After chemotherapy, the VEGF, MMP-9, CYFRA21-1 and CEA levels in two groups were significantly reduced (P<0.05), and the serological indexes in the observation group were lower than those in the control group (P<0.05). Both groups showed adverse reactions such as leukopenia, thrombocytopenia, and joint pain during chemotherapy, and were relieved after symptomatic treatment without significant difference. Conclusion Paclitaxel Injection combined with Apatinib Mesylate Tablets is effective in treatment of NSCLC. It can effectively improve the serological indexes of patients, and is worthy of clinical application and promotion.